CN117838665A - 一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 - Google Patents
一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 Download PDFInfo
- Publication number
- CN117838665A CN117838665A CN202211213869.5A CN202211213869A CN117838665A CN 117838665 A CN117838665 A CN 117838665A CN 202211213869 A CN202211213869 A CN 202211213869A CN 117838665 A CN117838665 A CN 117838665A
- Authority
- CN
- China
- Prior art keywords
- film
- oral instant
- forming material
- instant film
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 title claims abstract description 21
- 229960001956 rasagiline mesylate Drugs 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000004014 plasticizer Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000796 flavoring agent Substances 0.000 claims abstract description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 12
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000005520 cutting process Methods 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960003943 hypromellose Drugs 0.000 claims description 10
- 239000003086 colorant Substances 0.000 claims description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 8
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000003292 glue Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 150000001746 carotenes Chemical class 0.000 claims description 2
- 235000005473 carotenes Nutrition 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940097275 indigo Drugs 0.000 claims description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- -1 polyethylene terephthalate Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000010215 titanium dioxide Nutrition 0.000 claims description 2
- 238000004804 winding Methods 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000012528 membrane Substances 0.000 abstract description 6
- 210000000214 mouth Anatomy 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 description 57
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 208000027089 Parkinsonian disease Diseases 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于药物制剂技术领域,具体涉及一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法。本发明所述的口腔速溶膜剂,包含以下组分:药物、成膜材料、增塑剂、酸性稳定剂、矫味剂和色素。该口腔速溶膜在口腔中能迅速崩溶,口感好、释药速度快、可迅速起效,有利于提高患者尤其是儿童患者和老年患者的用药顺应性,且服用方便,解决了在无水的情况下不能及时服药的问题。
Description
技术领域
本发明属于药物制剂领域,具体涉及一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法。
背景技术
帕金森病是一种常见的中老年神经系统退行性疾病,主要以黑质多巴胺能神经元进行性退变和路易小体形成病理变化;纹状体区多巴胺递质降低,多巴胺与乙酰胆碱递质失衡的生理变化;震颤、肌强直、动作迟缓、姿势平衡障碍的运动症状和嗅觉减退、便秘、睡眠行为异常和抑郁等非运动症状的临床表现为显著特征。
雷沙吉兰(Rasagiline Mesylate)是一种新型选择性B型单胺氧化酶(MAO-B)抑制剂(MAOI),对于帕金森患者的运动症状有改善作用,主要推荐用于治疗早期的帕金森病患者,特别是早发型或者初治的帕金森患者,以及伴有剂末波动患者的联合治疗(与左旋多巴合用)。
目前市场上的甲磺酸雷沙吉兰剂型主要是片剂;其不足之处是起效慢,吸收效率低,且对于震颤麻痹患者和吞食困难的老年患者来说,服用不方便,顺应性差。
口腔速溶膜剂是一种在口腔内快速溶解的新剂型,具有下有优点:(1)口腔速溶膜遇唾液后即可快速崩解、迅速释放,快速起效;(2)无需咀嚼及用水送服,服用方便,具有较好的患者顺应性,无堵塞喉咙的危险,可作为传统口服片剂、胶囊等的替代剂型,可应用于小儿及吞咽困难的老年人或术后患者;(3)体积轻便小巧,独立包装,便于携带,相比于口崩片,辅料用量少,工艺简便,成本低,不易脆碎,便于储存和运输。
其中,成膜材料对口溶膜的质量影响至关重要。一方面,口溶膜需要在口腔中快速崩解成细小颗粒或进一步溶解成溶液态;另一方面,口溶膜剥离载体材料,剥离性需要适宜,干燥后对载体材料有一定粘性,不易脱落,利于后续工艺的剪裁包装;若剥离性差,膜不易剥离,影响剪裁时膜与载体材料的分离,不利于剪裁;若剥离性太好,上机剪裁时,膜与载体材料已经分离,不利于剪裁工艺,影响工艺顺畅性,所以剥离性应该保持适宜,确保剪裁工艺的顺畅性。
发明内容
有鉴于此,本发明的目的在于提供一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法,本发明通过选择合适的成膜材料、增塑剂、酸性稳定剂、矫味剂和着色剂,提供了一种口味良好、在口腔中迅速溶解,可迅速起效的甲磺酸雷沙吉兰口腔速溶膜剂,提高帕金森患者的用药顺应性。
技术方案
本发明涉及一种甲磺酸雷沙吉兰口腔速溶膜剂,含有:
甲磺酸雷沙吉兰1%-10%,
成膜材料20%-90%,
增塑剂5%-30%,
酸性稳定剂0.1%-2%,
矫味剂1%-5%,
着色剂0-2%。
所述的成膜材料选自聚乙烯醇、羟丙甲纤维素、羟丙基纤维素中的一种或两种以上的混合物。所述成膜材料为羟丙甲纤维素、聚乙烯醇中的一种或其组合。所述成膜材料选自聚乙烯醇5-88和羟丙甲纤维素E15,所述聚乙烯醇5-88和羟丙甲纤维素E15质量比为3:1-5:1。
所述的增塑剂选自聚乙二醇、甘油中的一种或其组合。
所述酸性稳定剂选自酒石酸、无水枸橼酸、苹果酸中的一种或多种。
所述矫味剂选自三氯蔗糖、安赛蜜、糖精钠、木糖醇中的一种或多种。
所述着色剂选自胭脂红、胡萝卜素、靛蓝、二氧化钛中的一种或多种。
所述的口腔速溶膜剂的制备方法,包括如下步骤:
(1)称取处方量的增塑剂分散于纯化水中,再称取处方量的成膜材料1分散于纯化水中溶胀,60~70℃水浴加热,搅拌至溶解;
(2)将处方量成膜材料2加入至步骤(1)所得溶液中,60~70℃水浴保温,搅拌至溶解;
(3)将步骤(1)所得溶液冷却至室温后,向所得溶液中加入处方量的药物、酸性稳定剂、矫味剂和遮光剂,搅拌均匀;
(4)将步骤(3)所得溶液静置消泡,将无气泡胶液在耐高温PET带上涂膜,40~60℃干燥,脱膜。
(5)将收卷膜剂进行剪裁、包装,控制片重差异±5%内,即得成品。
有益效果
本发明中的甲磺酸雷沙吉兰口溶膜具有以下优势:
(1)为甲磺酸雷沙吉兰增添了一种新剂型,填补了市场空白,为帕金森患者提供了更多的剂型选择,尤其是对传统药剂有抗拒心理的患者,本品薄膜状,可很好保护隐私性。
(2)服用方便,无需用水送服,无需咀嚼,同时无堵塞喉咙的危险,比普通片剂或胶囊,具有较好的患者顺应性,尤其适用于帕金森患者、吞咽困难的患者或术后患者。
(3)崩解迅速,起效快。本发明的口溶膜在口中可在30秒内快速崩解,使药物极快速溶出,比普通片剂或胶囊,大大缩短了崩解、溶出时间,能迅速吸收。
(4)口感好,无明显异味,无砂砾感,有利于提高患者服药地顺应性;
(5)相比于普通片剂和口崩片,工艺简便,成本低,不易脆碎,便于储存和运输;且工艺过程无粉尘飞扬,利于人员健康防护。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下通过实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
实施例1-4
口溶膜剂包括以下组分:药物活性成分、水溶性高分子成膜材料、增塑剂、稳定剂和矫味剂,所述药物活性成分为甲磺酸雷沙吉兰,所述水溶性高分子成膜材料分为羟丙甲基纤维素E5、羟丙甲基纤维素E15、聚乙烯醇5-88、羟丙基纤维素。
按照下表的处方组成,制成粘度适宜的胶液,涂布于PET离型膜上,于40-60℃进行干燥,剪裁成1.5cm*2.5cm大小的膜,即得成品。以外观性状、剥离性、韧性为考察指标,综合评价成膜材料。
处方组成如下:
实验结果:
从实施例1-4可以看出,聚乙烯醇5-88作为单一成膜剂时,成膜效果好,药膜外观均匀光滑,剥离性、柔韧性表现最为优异。
实施例5-10
口溶膜剂包括以下组分:药物活性成分、水溶性高分子成膜材料、增塑剂、稳定剂和矫味剂,所述药物活性成分为甲磺酸雷沙吉兰,所述水溶性高分子成膜材料为羟丙甲基纤维素E15+聚乙烯醇5-88(1:1、2:1、3:1、4:1、1:2、1:3)。
按照下表的处方组成,制成粘度适宜的胶液,涂布于PET离型膜上,于40-60℃进行干燥,剪裁成1.5cm*2.5cm大小的膜,即得成品。以外观性状、剥离性、韧性为考察指标,综合评价成膜材料。
处方组成如下:
原辅料组成 | 用量(g) |
甲磺酸雷沙吉兰 | 0.78 |
羟丙甲纤维素E15+聚乙烯醇5-88 | 15 |
聚乙二醇400 | 3.8 |
三氯蔗糖 | 0.40 |
无水枸橼酸 | 0.2 |
纯化水 | 90 |
成膜剂占比及结果如下:
从实施例1-5可以看出,羟丙甲纤维素E15和聚乙烯醇5-88作为成膜剂,成膜效果较好,药膜外观均匀光滑,剥离性、柔韧性、耐折度较好,因此可以选择羟丙甲纤维素E15和聚乙烯醇5-88中的一种或多种作为成膜剂,羟丙甲纤维素E15和聚乙烯醇5-88不同比例下成膜效果,比例为4:1时,成膜效果最好。
实施例11-12
本实施例提供一种口溶膜剂,所述口溶膜剂包括以下组分:药物活性成分、水溶性高分子成膜材料、增塑剂、稳定剂和矫味剂,所述药物活性成分为甲磺酸雷沙吉兰,所述增塑剂为聚乙二醇400和甘油。
按照下表的处方组成,制成粘度适宜的胶液,涂布于PET离型膜上,于40-60℃进行干燥,剪裁成1.5cm*2.5cm大小的膜,即得成品。以外观性状、剥离性、韧性为考察指标,综合评价成膜材料。
处方组成如下:
实验结果:
评价指标 | 实施例11 | 实施例12 |
外观性状 | 透明药膜,表面光滑 | 透明药膜,表面光滑 |
剥离性 | 易脱膜 | 易脱膜 |
韧性 | 膜硬度适中,柔韧性高 | 膜硬度适中,柔韧性良好 |
从实施例11-12可以看出,聚乙二醇400和甘油作为单一增塑剂时,成膜效果均优异,药膜外观均匀光滑,剥离性、柔韧性、耐折度均较好,因此可以选择聚乙二醇400和甘油中的一种或多种作为成膜剂。
实施例13
本实施例提供一种口溶膜剂,所述口溶膜剂包括以下组分:药物活性成分、水溶性高分子成膜材料、增塑剂、稳定剂、矫味剂、着色剂,所述药物活性成分为甲磺酸雷沙吉兰,所述着色剂为二氧化钛。
按照下表的处方组成,制成粘度适宜的胶液,涂布于PET离型膜上,于40-60℃进行干燥,剪裁成1.5cm*2.5cm大小的膜,即得成品。以外观性状、剥离性、韧性为考察指标,综合评价成膜材料。
处方组成如下:
原辅料组成 | 用量(g) |
甲磺酸雷沙吉兰 | 0.78 |
羟丙甲纤维素E15 | 11.84 |
聚乙烯醇5-88 | 3.09 |
聚乙二醇400 | 3.76 |
三氯蔗糖 | 0.40 |
无水枸橼酸 | 0.02 |
二氧化钛 | 0.10 |
纯化水 | 90 |
二氧化钛作为着色剂时,制成的膜剂外观呈奶白色,磨砂感,易脱模,膜硬度适中,柔韧性良好。
Claims (9)
1.一种甲磺酸雷沙吉兰口腔速溶膜剂,其特征在于,包含以下处方组分:
甲磺酸雷沙吉兰1%-10%,
成膜材料20%-90%,
增塑剂5%-30%,
酸性稳定剂0.1%-2%,
矫味剂1%-5%,
着色剂0-2%。
2.如权利要求1所述的口腔速溶膜剂,其特征在于,所述的成膜材料选自聚乙烯醇、羟丙甲纤维素、羟丙基纤维素中的一种或两种以上的混合物。
3.如权利要求1所述的口腔速溶膜剂,其特征在于,所述成膜材料为羟丙甲纤维素、聚乙烯醇中的一种或其组合。
4.如权利要求1所述的口腔速溶膜剂,其特征在于,所述成膜材料选自聚乙烯醇5-88和羟丙甲纤维素E15,所述聚乙烯醇5-88和羟丙甲纤维素E15质量比为3:1-5:1。
5.如权利要求1所述的口腔速溶膜剂,其特征在于,所述的增塑剂选自聚乙二醇、甘油中的一种或其组合。
6.如权利要求1所述的口腔速溶膜剂,其特征在于,所述酸性稳定剂选自酒石酸、无水枸橼酸、苹果酸中的一种或多种。
7.如权利要求1所述的口腔速溶膜剂,其特征在于,所述矫味剂选自三氯蔗糖、安赛蜜、糖精钠、木糖醇中的一种或多种。
8.如权利要求1所述的口腔速溶膜剂,其特征在于,所述着色剂选自胭脂红、胡萝卜素、靛蓝、二氧化钛中的一种或多种。
9.权利要求1-8任一权利要求所述的口腔速溶膜剂的制备方法,其特征在于,包括如下步骤:
(1)称取处方量的增塑剂分散于纯化水中,再称取处方量的成膜材料1分散于纯化水中溶胀,60~70℃水浴加热,搅拌至溶解;
(2)将处方量成膜材料2加入至步骤(1)所得溶液中,60~70℃水浴保温,搅拌至溶解;
(3)将步骤(1)所得溶液冷却至室温后,向所得溶液中加入处方量的药物、酸性稳定剂、矫味剂和遮光剂,搅拌均匀;
(4)将步骤(3)所得溶液静置消泡,将无气泡胶液在耐高温PET带上涂膜,40~60℃干燥,脱膜。
将收卷膜剂进行剪裁、包装,控制片重差异±5%内,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211213869.5A CN117838665A (zh) | 2022-09-30 | 2022-09-30 | 一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211213869.5A CN117838665A (zh) | 2022-09-30 | 2022-09-30 | 一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117838665A true CN117838665A (zh) | 2024-04-09 |
Family
ID=90538661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211213869.5A Pending CN117838665A (zh) | 2022-09-30 | 2022-09-30 | 一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117838665A (zh) |
-
2022
- 2022-09-30 CN CN202211213869.5A patent/CN117838665A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karki et al. | Thin films as an emerging platform for drug delivery | |
DE69930964T2 (de) | Zusammensetzungen und verfahren für mukosale abgabe | |
AU2002246916B2 (en) | Bioadhesive cell foam film of sustained-release delivery | |
US8900629B2 (en) | Rapidly dissolving pharmaceutical compositions comprising pullulan | |
RU2445977C2 (ru) | Водорастворимые пленки, содержащие маловязкие альгинаты | |
Bhura et al. | A review on fast dissolving film | |
JP2016525572A (ja) | 経口分散性フィルム | |
JP2008517935A (ja) | ジクロフェナクを含む医薬組成物 | |
US20100266687A1 (en) | Improved tablet coating | |
TW202228682A (zh) | 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病 | |
CN111939140A (zh) | 阿立哌唑口腔速溶膜剂及其制备方法 | |
Karthik et al. | A Review on Fast Dissolving Oral Films | |
Mushtaque et al. | Novelty and Compliance of Oral Fast Dissolving Thin Film–A Patient Friendly Dosage Form | |
CN100386071C (zh) | 一种治疗咳喘、慢性支气管炎的药物 | |
CN103860523A (zh) | 马来酸氯苯那敏口腔速溶膜及其制备方法 | |
CN113440499B (zh) | 叶酸口溶膜剂及其制备方法 | |
CN108348502A (zh) | 软性抗胆碱能酯的方法和组合物 | |
CN117838665A (zh) | 一种甲磺酸雷沙吉兰口腔速溶膜剂及其制备方法 | |
CN109771395A (zh) | 一种含有槲皮素的口腔黏膜剂及其制备方法 | |
CN112089708B (zh) | 一种氯雷他定口腔分散膜剂及其制备方法 | |
Kumar et al. | A comprehensive review on pharmaceutical Oral dissolving films | |
CN101732286B (zh) | 伏格列波糖膜剂及其制备方法 | |
KR20210018165A (ko) | 대마의 오일 추출물 또는 파우더 추출물을 제제의 원료로 함유하는 구강 내 속붕해 제제 | |
JP7537032B2 (ja) | ラサギリン又はその医薬用塩の舌下フィルム剤及びその製造方法、使用 | |
CN118615260A (zh) | 一种吡仑帕奈口溶膜的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |